Soft tissue sarcomas are rare solid tumors that are being increasingly classified and treated by subtype. Approximately 12,020 people will be diagnosed with a soft tissue sarcoma in the United States ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot ...

Soft tissue sarcomas rarely metastasize to the heart, with cardiac involvement seen in less than 0.03% of cases. Metastatic heart disease presents diagnostic challenges due to nonspecific symptoms, ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study ...

Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma Over three-fold increase in tumour ...

Although relatively rare, soft tissue sarcoma after breast cancer treatment was linked most strongly to treatment with radiation, according to data from two large U.S. cohorts of breast cancer ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A novel T-cell receptor therapy showed promising antitumor activity in patients with advanced soft ...

Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study ...